{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:28Z","timestamp":1740107008483,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00520-023-07664-z","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T03:02:50Z","timestamp":1679367770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of a multidisciplinary team\u2019s role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia"],"prefix":"10.1007","volume":"31","author":[{"given":"Vera","family":"Pervitsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Moskoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxie","family":"Kneen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Leija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Sawicky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret Li","family":"Krackeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4921-5809","authenticated-orcid":false,"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2774-0899","authenticated-orcid":false,"given":"Ryan","family":"Beechinor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"unstructured":"Acute Myeloid Leukemia Treatment (PDQ\u00ae). NIH National Cancer Institute. https:\/\/www.cancer.gov\/types\/leukemia\/patient\/adult-aml-treatment-pdq. Published 2021. Accessed 25 Sept 2021","key":"7664_CR1"},{"unstructured":"Leukemia - acute myeloid - AML: statistics. https:\/\/www.cancer.net\/cancer-types\/leukemia-acute-myeloid-aml\/statistics. Accessed 25 Sept 2021","key":"7664_CR2"},{"issue":"7","key":"7664_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"unstructured":"Altman JK, Lurie RH, Appelbaum FR et al (2021) NCCN guidelines acute myeloid leukemia (age\u00a0\u2265\u00a018\u00a0years). NCCN 3.2021","key":"7664_CR4"},{"issue":"10","key":"7664_CR5","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Maiti A, Rausch CR et al (2020) 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724\u2013e736. https:\/\/doi.org\/10.1016\/S2352-3026(20)30210-6","journal-title":"Lancet Haematol"},{"issue":"1","key":"7664_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"issue":"2","key":"7664_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A et al (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19(2):216\u2013228. https:\/\/doi.org\/10.1016\/S1470-2045(18)30010-X","journal-title":"Lancet Oncol"},{"issue":"4","key":"7664_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM et al (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1513257","journal-title":"N Engl J Med"},{"issue":"3","key":"7664_CR9","first-page":"86","volume":"2","author":"C Talati","year":"2021","unstructured":"Talati C, Sweet KL, Pollyea DA et al (2021) Moving the treatment of acute myeloid leukemia to the outpatient setting\u202f: current expert perspectives and consensus findings. J Clin Hematol 2(3):86\u201394","journal-title":"J Clin Hematol"},{"issue":"3","key":"7664_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/10781552211072467","volume":"28","author":"H Wyatt","year":"2022","unstructured":"Wyatt H, Zuckerman AD, Hughes ME, Arnall J, Miller R (2022) Addressing the challenges of novel oncology and hematology treatments across sites of care: specialty pharmacy solutions. J Oncol Pharm Pract 28(3):627\u2013634. https:\/\/doi.org\/10.1177\/10781552211072467","journal-title":"J Oncol Pharm Pract"},{"key":"7664_CR11","doi-asserted-by":"publisher","first-page":"512016","DOI":"10.1155\/2015\/512016","volume":"2015","author":"B Anders","year":"2015","unstructured":"Anders B, Shillingburg A, Newton M (2015) Oral antineoplastic agents: assessing the delay in care. Chemother Res Pract 2015:512016. https:\/\/doi.org\/10.1155\/2015\/512016","journal-title":"Chemother Res Pract"},{"issue":"1","key":"7664_CR12","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1200\/JOP.2016.012302","volume":"13","author":"JL Niccolai","year":"2017","unstructured":"Niccolai JL, Roman DL, Julius JM, Nadour RW (2017) Potential obstacles in the acquisition of oral anticancer medications. J Oncol Pract 13(1):e29\u2013e36. https:\/\/doi.org\/10.1200\/JOP.2016.012302","journal-title":"J Oncol Pract"},{"issue":"12","key":"7664_CR13","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","volume":"33","author":"BA Jonas","year":"2019","unstructured":"Jonas BA, Pollyea DA (2019) How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 33(12):2795\u20132804. https:\/\/doi.org\/10.1038\/s41375-019-0612-8","journal-title":"Leukemia"},{"issue":"5","key":"7664_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41408-021-00481-9","volume":"11","author":"CM Pabon","year":"2021","unstructured":"Pabon CM, Li Z, Hennig T et al (2021) Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant. Blood Cancer J 11(5):92. https:\/\/doi.org\/10.1038\/s41408-021-00481-9","journal-title":"Blood Cancer J"},{"unstructured":"Foundation KF. Hospital adjusted expenses per inpatient day by ownership. https:\/\/www.kff.org\/health-costs\/state-indicator\/expenses-per-inpatient-day-by-ownership\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. Published 2021. Accessed 25 Apr 2022","key":"7664_CR15"},{"issue":"6","key":"7664_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3324\/HAEMATOL.2011.040220","volume":"96","author":"RB Walter","year":"2011","unstructured":"Walter RB, Lee SJ, Gardner KM et al (2011) Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. Haematologica 96(6):914\u2013917. https:\/\/doi.org\/10.3324\/HAEMATOL.2011.040220","journal-title":"Haematologica"},{"doi-asserted-by":"publisher","unstructured":"Moore NJ, Othus M, Halpern AB et al (2021) Financial implications of early hospital discharge after AML-like induction chemotherapy: a 4-year retrospective analysis. J Natl Compr Cancer Netw 1(aop):1\u201310. https:\/\/doi.org\/10.6004\/JNCCN.2020.7683","key":"7664_CR17","DOI":"10.6004\/JNCCN.2020.7683"},{"issue":"11","key":"7664_CR18","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.7150\/JCA.56171","volume":"12","author":"H Zhang","year":"2021","unstructured":"Zhang H, Yu J, Wei Z, Wu W, Zhang C, He Y (2021) The effect of multidisciplinary team discussion intervention on the prognosis of advanced colorectal cancer. J Cancer 12(11):3307. https:\/\/doi.org\/10.7150\/JCA.56171","journal-title":"J Cancer"},{"doi-asserted-by":"publisher","unstructured":"Horvath LE, Yordan E, Malhotra D et al (2010) Multidisciplinary care in the oncology setting: historical perspective and data from lung and gynecology multidisciplinary clinics. J Oncol Pract 6(6). https:\/\/doi.org\/10.1200\/JOP.2010.000073","key":"7664_CR19","DOI":"10.1200\/JOP.2010.000073"},{"key":"7664_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/HSC.13642","author":"C Parker","year":"2021","unstructured":"Parker C, Berkovic D, Wei A, Zomer E, Liew D, Ayton D (2021) \u201cIf i don\u2019t work, i don\u2019t get paid\u201d: an Australian qualitative exploration of the financial impacts of acute myeloid leukaemia. Health Soc Care Community. https:\/\/doi.org\/10.1111\/HSC.13642","journal-title":"Health Soc Care Community"},{"doi-asserted-by":"publisher","unstructured":"Bewersdorf JP, Shallis RM, Wang R et al (2019) Healthcare expenses for treatment of acute myeloid leukemia. 101080\/1747408620191627869 12(8):641\u2013650. https:\/\/doi.org\/10.1080\/17474086.2019.1627869","key":"7664_CR21","DOI":"10.1080\/17474086.2019.1627869"},{"issue":"2","key":"7664_CR22","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1200\/op.21.00168","volume":"18","author":"AY Jeong","year":"2022","unstructured":"Jeong AY, Schwartz EB, Roman AR et al (2022) Characterizing out-of-pocket payments and financial assistance for patients prescribed abiraterone and enzalutamide at an academic cancer center specialty pharmacy. JCO Oncol Pract 18(2):e284\u2013e292. https:\/\/doi.org\/10.1200\/op.21.00168","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"7664_CR23","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/AJH.26190","volume":"96","author":"A Apel","year":"2021","unstructured":"Apel A, Moshe Y, Ofran Y et al (2021) Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. Am J Hematol 96(7):790\u2013795. https:\/\/doi.org\/10.1002\/AJH.26190","journal-title":"Am J Hematol"},{"key":"7664_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000549","author":"J Feld","year":"2021","unstructured":"Feld J, Tremblay D, Dougherty M et al (2021) Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies. HemaSphere. https:\/\/doi.org\/10.1097\/HS9.0000000000000549","journal-title":"HemaSphere"},{"doi-asserted-by":"publisher","unstructured":"Keruakous A, Saleem R, Asch AS (2020) Venetoclax-induced tumor lysis syndrome in acute myeloid leukemia: real world experience. 101200\/JCO20203815_suppl.e19542. 38(15_suppl):e19542-e19542. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_SUPPL.E19542","key":"7664_CR25","DOI":"10.1200\/JCO.2020.38.15_SUPPL.E19542"},{"issue":"9","key":"7664_CR26","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1007\/S00520-021-06119-7\/TABLES\/2","volume":"29","author":"A Pelcovits","year":"2021","unstructured":"Pelcovits A, Moore J, Bakow B, Niroula R, Egan P, Reagan JL (2021) Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia. Support Care Cancer 29(9):5323\u20135327. https:\/\/doi.org\/10.1007\/S00520-021-06119-7\/TABLES\/2","journal-title":"Support Care Cancer"},{"issue":"20","key":"7664_CR27","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/BLOODADVANCES.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC, Gutman JA, Purev E et al (2019) Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv 3(20):2911\u20132919. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2019000243","journal-title":"Blood Adv"},{"unstructured":"Azacitidine, venetoclax, and gilteritinib in treating patients with recurrent\/refractory FLT3-mutated acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome\/myeloproliferative neoplasm. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04140487?term=gilteritinib+azacitidine+venetoclax&draw=2&rank=1. Accessed 29 May 2022","key":"7664_CR28"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07664-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07664-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07664-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T08:09:34Z","timestamp":1681546174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07664-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["7664"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07664-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the study procedures were approved by our Institutional Review Board, and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Brian A Jonas reports consultant\/advisor following entities which are unrelated to this content: AbbVie, BMS, Genentech, Gilead, GlycoMimetics, Jazz, Pfizer, Servier, Takeda, Tolero, and Treadwell; protocol steering committee for GlycoMimetics; data monitoring committee for Gilead; travel reimbursement from AbbVie; and research funding to his institution from 47, AbbVie, Accelerated Medical Diagnostics, Amgen, Aptose, AROG, BMS, Celgene, Daiichi Sankyo, F. Hoffmann-La Roche, Forma, Genentech\/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Incyte, Jazz, Loxo Oncology, LP Therapeutics, Pfizer Inc., Pharmacyclics, Sigma Tau, and Treadwell. Ryan J Beechinor reports having received funding\/compensation for consulting and\/or research activities from the following entities which are unrelated to this content: National Institute of Health (NIH), Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD), Children\u2019s Oncology Group (COG), IQVIA, Cempra Pharmaceutics, Oncology Reimbursement Management, Aptitude Health, The Dedham Group, Trinity Life Sciences, and Pfizer Inc. All remaining authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"224"}}